ASH 2025: JTCC Researchers Shape the Future of Blood Cancer Care

January 20, 2026

Investigators from Hackensack University Medical Center’s John Theurer Cancer Center (JTCC) — a leading research partner of the NCI-designated Lombardi Comprehensive Cancer Center at Georgetown University, and the best cancer center in New Jersey — presented 65 studies at the 67th American Society of Hematology (ASH) Annual Meeting, held December 6–9, 2025, in Orlando.

The 2025 studies mark JTCC’s largest and most diverse scientific contributions to ASH so far, showcasing innovations in cell therapy, targeted agents, AI-powered diagnostics, stem cell transplantation, and real-world evidence across nearly all hematologic diseases — including leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms and noncancerous blood disorders.

“John Theurer Cancer Center continues to help shape the future of blood cancer care,” said André Goy, M.D., chair, physician-in-chief and vice president of Oncology at Hackensack Meridian Health. “Our teams are redefining transplantation, advancing CAR-T science, and co-leading trials that test next-generation targeted therapies and immunotherapies. The depth and breadth of our ASH presentations underscore our mission: to bring transformational science rapidly to the clinic for patients with blood cancers and other serious blood disorders.”

Learn more about JTCC’s research presented at ASH 2025.

Learn more about our innovations in cancer care.